Tvardi Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-18.2M | $-29.4M | $-118.5M | $-85.5M | $-88.4M | $8.4M | $-106.4M | $-74.0M |
| Depreciation & Amortization | $95.0K | $95.0K | $259.0K | $248.0K | $248.0K | $209.0K | $198.0K | $370.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.4M | $319.0K | $13.7M | $17.7M | $20.8M | $14.8M | $12.6M | $9.5M |
| Net Cash from Operating Activities | $-23.5M | $-18.3M | $-92.1M | $-78.7M | $-60.1M | $-5.5M | $-109.2M | $-22.3M |
| Investing Activities | ||||||||
| Capital Expenditures | — | $1.0M | $2.4M | $43.0K | $39.0K | $349.0K | $18.0K | $73.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-10.1M | $48.7M | $43.5M | $128.7M | $-4.8M | $-20.3M | $-30.5M | $-82.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $22.7M | $27.0M | $38.2M | $311.0K | $46.6M | $39.1M | $142.6M | $110.8M |
| Net Change in Cash | $-10.9M | $8.7M | — | — | — | — | — | — |
| Free Cash Flow | — | $-19.4M | $-94.5M | $-78.8M | $-60.1M | $-5.8M | $-109.2M | $-22.4M |